

RECEIVED  
CENTRAL FAX CENTER

JUN 30 2004

OFFICIAL



901 California Avenue Palo Alto, CA 94304-1104 Main: 650 • 496-6400 FAX: 650 • 496-1200

**FAX TRANSMITTAL SHEET****NO. OF PAGES** (including this page): 7**TO:** Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**Attn:** Examiner  
**Art Unit:** Unknown  
**FAX:** (703) 872-9306**FROM:** Sheela Mohan-Peterson  
**DATE:** June 30, 2004**RE:** Docket No.: DX0670KB1C  
USSN: 10/777,521  
Filed: February 11, 2004  
Title: Isolated Mammalian Monocyte Cell Genes; Related Reagents**Any difficulty with this facsimile, please call: Melanie Lyons at (650) 496-1183****Documents attached:**

- Transmittal (1 page)
- IDS and Form PTO/SB/08 (5 pages)

I hereby certify that this correspondence is being facsimile transmitted to the USPTO to:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date  
indicated below:

June 30, 2004  
Melanie Lyons

**CONFIDENTIALITY NOTE:** This sheet and/or the document(s) accompanying it contain information belonging to DNAX which is confidential and/or legally privileged. The information is intended only for the use of the person or entity named above. If you have received this fax in error, please immediately notify us by telephone or return Fax.

PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

**TRANSMITTAL  
FORM**


(to be used for all correspondence after initial filing)

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	10/777,521	
	Filing Date	02/11/2004	
	First Named Inventor	Gosse Jan ADEMA	
	Art Unit	Unknown	
	Examiner Name	Unknown	
Total Number of Pages In This Submission	7	Attorney Docket Number	DX0670KB1C

**ENCLOSURES (Check all that apply)**


<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement (2 pages)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<b>Other Enclosures/Remarks:</b> <ul style="list-style-type: none"><li>• Form PTO/SB/08 (3 pages)</li><li>• Fax Transmittal Sheet (1 page)</li></ul>	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or individual	Sheela Mohan-Peterson, Reg. No. 41,201 DNAX Research, Inc. 901 California Ave. Palo Alto, CA 94304-1104
Signature	
Date	30-June-2004

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this date indicated below:

Typed or printed	MELANIE LYONS		
Signature		Date	June 30, 2004

This collection of information is required by 37 CFR 1.5. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

JUN 30 2004

003/007

OFFICIAL

Attorney Docket: DX0670KB1C

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re application of:

Gosse Jan ADEMA, et al.

Application No.: 10/777,521

Filed: February 11, 2004

For: Isolated Mammalian Monocyte Cell  
Genes; Related Reagents

Examiner: Not yet assigned

Art Unit: Not yet assigned

Conf. No.: Not yet assigned

I hereby certify that this correspondence is being facsimile  
transmitted to the U.S. Patent and Trademark Office,  
(703) 872-9306, Attn. Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450, on June 30, 2004

by:

  
MELANIE LYONS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

The materials as listed in the attached form PTO/SB/08 are brought to the Examiner's attention pursuant to the duty of disclosure under 37 C.F.R. § 1.56, § 1.97, and § 1.98. Attached please find Form PTO/SB08 listing references AA-AU.

All references listed on the attached form PTO/SB/08 have been previously cited either by Applicants or the Examiner in the following parent applications:

1. USSN 08/985,950, filed December 5, 1997, now US Patent No. 6,140,076;
2. USSN 09/546,049, filed April 10, 2000, now US Patent No. 6,479,638; and
3. USSN 10/290,631, filed November 8, 2002, currently pending.

Copies of the previously cited references should be available in these files. As such, these references will not be provided absent a specific request.

Citation of these documents should not be construed as a representation that the documents are in fact material or are in fact prior art with respect to the instant invention. The Examiner should not make any inference relating to the relative pertinence of cited references

based upon the order in which the art is presented. Citation of these documents should not be construed as a representation that a search has been made or that more pertinent art may not be in existence.

Applicants request that the Examiner fully consider the art cited in the attached PTO/SB/08 form. Applicants further request that the Patent and Trademark Office list all such art on the front of any patent issuing from this application.

Applicants believe no fee is required for filing this document; however, if such a fee is required the Commissioner is hereby authorized to charge DNAX Research Institute Deposit account no. 04-1239.

Respectfully submitted,

Date: 30-June-2004

By: Sheela Mohan-Peterson  
Sheela Mohan-Peterson, Reg. No. 41,201  
Attorney for Applicants

Customer No. 28008  
DNAX Research, Inc.  
901 California Avenue  
Palo Alto, CA 94304-1104  
Telephone (Switchboard): (650) 496-6400  
Telephone No. (Direct): (650) 496-1244  
Facsimile No.: (650) 496-1200



PTO/SE/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/777,521
				Filing Date	February 11, 2004
				First Named Inventor	Gosse Jan ADEMA, et al.
				Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	2	of	3	Attorney Docket Number	DX0670KB1C

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AE	Mariana C. Castells, <i>et al.</i> , <u>J. Biological Chemistry</u> , 269(11):8393-8401, 1994. "Cloning of the gp49B Gene of the Immunoglobulin Superfamily and Demonstration That One of Its Two Products Is an Early-expressed Mast Cell Surface Protein Originally Described as gp49"	
	AF	Marco Colonna and Jacqueline Samaridis, <u>SCIENCE</u> , 268:405-408, April 21, 1998. "Cloning of Immunoglobulin-Superfamily Members Associated with HLA-C and HLA-B Recognition by Human Natural Killer Cells"	
	AG	M. Colonna and J. Samaridis, <u>GenBank</u> , Entrez Browser Protein Query, Accession Number 1171729, Database source: <u>Swiss-Prot</u> , Accession Number P43630, November 1, 1995. "Cloning of Immunoglobulin-Superfamily Members Associated with HLA-C and HLA-B Recognition by Human Natural Killer Cells"	
	AH	M. Colonna, <i>et al.</i> , <u>Transplantation Proceedings</u> , 28(6):3035, December 1996. "Human Killer Inhibitory Receptors: Specificity for HLA-Class 1 Molecules and Mechanisms of Signal Transduction"	
	AI	L. Hillier, <i>et al.</i> , <u>Gen Bank</u> , Accession No. H26010, July 10, 1995. "The WashU-Merck EST Project"	
	AJ	David G. Jackson, <i>et al.</i> , <u>Eur. J. Immunol.</u> , 22(5):1157-1163, 1992. "Molecular cloning of a novel member of the immunoglobulin gene superfamily homologous to the polymeric immunoglobulin receptor"	
	AK	Vladimír Korinek, <i>et al.</i> , <u>Immunogenetics</u> , 33(2):108-112, February 1, 1991. "The human leukocyte antigen CD48 (MEM-102) is closely related to the activation marker Blast-1"	
	AL	Eric O. Long, <i>et al.</i> , <u>Immunology Today</u> , 17(2):100, February 1996. "Inhibitory MHC class 1 receptors and T cells: a standard nomenclature"	
	AM	Charles R. Maliszewski, <i>et al.</i> , <u>J. Exp. Med.</u> , 172:1665-1672, December 1990. "Expression Cloning of a Human Fc Receptor for IgA"	
	AN	Linde Meygaard, <i>et al.</i> , <u>Immunity</u> , 7:283-290, August 1997. "LAIR-1, a Novel Inhibitory Receptor Expressed on Human Mononuclear Leukocytes"	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SE/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/777,521
				Filing Date	February 11, 2004
				First Named Inventor	Gosse Jan ADEMA, et al.
				Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	3	of	3	Attorney Docket Number	DX0670KB1C

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	AO	LI Shen, et al., <u>J. Immunology</u> , 152:4080-4086, 1994. "Lipopolysaccharide and Cytokine Augmentation of Human Monocyte IgA Receptor Expression and Function"		
	AP	J. Samaridis and M. Colonna, <u>GenBank</u> , Entrez Browser Nucleotide Query, Accession Number U82279, March 27, 1997. "Cloning of novel immunoglobulin-superfamily receptors expressed on human myeloid and lymphoid cells. Structural evidence for new stimulatory and inhibitory pathways"		
	AQ	J. Samaridis and M. Colonna, <u>Eur. J. Immunol.</u> , 27:660-665, 1997. "Cloning of Novel Immunoglobulin Superfamily Receptors Expressed on Human Myeloid and Lymphoid Cells"		
	AR	Y. Sibille, et al., <u>Eur. Respir J.</u> , 7:1111-1119, 1994. "Fc alpha-receptor expression on the myelomonocytic cell line THP-1: comparison with human alveolar macrophages"		
	AS	Robert Strausberg, <u>GenBank</u> , Accession No. AA572674, September 12, 1997. "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index"		
	AT	WashU-Merck No. yw77c11.s1, <u>GenBank</u> , Accession No. N26404, December 29, 1997.		
	AU	G. Zhang, et al., <u>J. Immunol.</u> 155 : 1534-1541, 1995. "Identification of a Novel Class of Mammalian Fcγ Receptor"		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.99. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-796-9199) and select option 2.